In this review we highlight the key points of the systemic treatment of advanced metastatic MTC providing an overview of the treatments developed in the last years, from MKI to the highly selective RET inhibitors, up to the radionuclide therapies. This evidence concerns the gene RET and medullary thyroid gland carcinoma.